1 October 2024
Oxford Nanopore
Technologies plc
Dr Daniel Mahony
appointed as Non-Executive Director
Oxford Nanopore Technologies plc
(LSE: ONT) (''Oxford Nanopore'' or ''the Group''), the company
delivering a new generation of nanopore-based molecular sensing
technology, is pleased to announce that Dr Daniel Mahony will be
joining the Group as a Non-Executive Director with effect from 1
October 2024.
Daniel brings extensive sector
experience to help accelerate Oxford Nanopore's commercial
traction, with more than 25 years as a global healthcare investor
specialising in biotechnology, medical technology and healthcare
services. As Senior Partner in Growth Investments
at Novo Holdings, Daniel will serve as a critical sounding board to
the Group as it continues to advance its technology platform
to address a significant commercial opportunity in
biopharmaceuticals. In addition, he currently
chairs the UK BioIndustry Association and is a Non-Executive
Director of the Wellcome Sanger Institute.
Prior to joining Novo Holdings,
Daniel co-founded the healthcare business unit at
Polar Capital in London, growing it to more than $4 billion in
assets under management. He was formerly a Senior Research Analyst
at Morgan Stanley in London, an Analyst at ING Barings Furman Selz
in New York, and completed his postdoctoral work at DNAX Research
Institute in Palo Alto.
Dr Guy Harmelin, a non-executive
director of the Group, who has served on the Board
since 2020, has informed the Board of his intention to step
down from the Board with effect from today. Dr Guy
Harmelin, is stepping down to focus on various other Directorship
responsibilities.
Duncan Tatton-Brown, Chair of Oxford Nanopore,
said: "We are extremely pleased to welcome Daniel to
the board as Non-Executive Director of Oxford Nanopore. Daniel's
deep knowledge of the biopharma sector, combined with his
understanding of Oxford Nanopore's opportunity to drive value
across the biopharma development pipeline, position him as an ideal
source of expertise to support the company's commercial expansion
into this space. I would like to thank Guy, our outgoing
non-executive director for his outstanding support overall and
contribution in helping the Group transition from a private to a
public company during his tenure."
Dr
Daniel Mahony, incoming Non-Executive Director of Oxford Nanopore,
said: "This is an exciting time for Oxford Nanopore
with its expanding opportunity in biopharma, where rapid
sequencing, richer data and a streamlined platform can support
discovery and delivery of new biopharmaceuticals. I look forward to
bringing my industry expertise to bear as Oxford Nanopore executes
against its exciting growth plans in this
sector."
Dr
Gordon Sanghera, Chief Executive Officer of Oxford Nanopore,
said: "Daniel brings substantial strategic
experience to support Oxford Nanopore's commercial growth in the
life sciences and specifically the biopharma market. His
perspectives will be invaluable as we continue to expand the use of
our technology to address the needs of this industry, and I look
forward to working with Daniel as we enter this next phase. I also
would like to thank Guy, our outgoing non-executive director, for
his insight and guidance during his tenure on the board. We
appreciate his significant contribution and wish him well in his
next chapter."
Novo Holdings is a shareholder in
Oxford Nanopore and led the recent £80 million equity placing. The
decision to appoint Dr Mahony to the Board of Oxford Nanopore
reflects his considerable industry expertise and the value he
brings to the Board.
This announcement is made pursuant to
Listing Rule 9.6.11R. There are no other details required to
be disclosed under Listing Rule 9.6.13R.
-ENDS-
For further information, please
contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media:
media@nanoporetech.com
Teneo (communications adviser to the Group)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal
is to bring the widest benefits to society through enabling the
analysis of anything, by anyone, anywhere. The Group has developed
a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and
scalable analysis of DNA and RNA. The technology is used in
more than 125 countries, to understand the biology of humans,
plants, animals, bacteria, viruses and environments as well as to
understand diseases such as cancer. Oxford Nanopore's
technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.
For more information please
visit: www.nanoporetech.com